1. Home
  2. VGZ vs ZNTL Comparison

VGZ vs ZNTL Comparison

Compare VGZ & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vista Gold Corp

VGZ

Vista Gold Corp

HOLD

Current Price

$1.68

Market Cap

316.8M

Sector

N/A

ML Signal

HOLD

Logo Zentalis Pharmaceuticals Inc.

ZNTL

Zentalis Pharmaceuticals Inc.

HOLD

Current Price

$5.01

Market Cap

289.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VGZ
ZNTL
Founded
1983
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
316.8M
289.0M
IPO Year
1996
2020

Fundamental Metrics

Financial Performance
Metric
VGZ
ZNTL
Price
$1.68
$5.01
Analyst Decision
Strong Buy
Buy
Analyst Count
2
5
Target Price
$3.75
$6.60
AVG Volume (30 Days)
3.0M
1.4M
Earning Date
05-12-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
18.03
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.91
$1.21
52 Week High
$3.13
$6.95

Technical Indicators

Market Signals
Indicator
VGZ
ZNTL
Relative Strength Index (RSI) 40.79 62.05
Support Level $1.57 $3.53
Resistance Level $1.89 $5.11
Average True Range (ATR) 0.10 0.42
MACD -0.01 0.03
Stochastic Oscillator 42.27 60.54

Price Performance

Historical Comparison
VGZ
ZNTL

About VGZ Vista Gold Corp

Vista Gold Corp operates as a development-stage company in the gold mining industry. Its flagship asset is the Mt Todd Gold Project, a development-stage gold deposit located in the Tier-1 jurisdiction of Northern Territory, Australia. Mt Todd offers a large gold mineral reserve, development optionality, expansion opportunities, exploration upside, local infrastructure, community support, and demonstrated economic feasibility. It operates in one reportable segment, consisting of acquisition, exploration and evaluation activities which are focused on Australia.

About ZNTL Zentalis Pharmaceuticals Inc.

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.

Share on Social Networks: